Hesperos, Inc.
Orlando, FL Hesperos Inc.
- UEI
- R1LSLA5YJMJ9
- CAGE
- 79R15
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Physical address
- 12501 Research Pkwy #100, Orlando, FL 32826, USA
- Website
- hesperosinc.com
- Founded
- 2015
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Industrials
- Commercial & Professional Services
- Professional Services
- SIC code
- 87 Engineering & Management Services
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Expanded implementation of a human-based malaria-on-a-chip phenotypic disease model for the evaluation of therapeutic… | National Institute of Allergy and Infectious Diseases | $1,000,000 | |
| Human neuromuscular junction platform to evaluate botulinum toxin potency - project summary: botulinum neurotoxin (bont)… | National Center for Advancing Translational Sciences | $720,882 | |
| Human neuromuscularjunction platform to evaluate botulinum toxin potency | National Center for Advancing Translational Sciences | $3,000,000 | |
| Hesperos, LLC:1280468 [24-000168] | Office of Logisitics and Acquisition Operations | $32,235 | |
| Modulatory role of blood-brain-barrier and enzymatic activity in an innovative human model of cholinergic drug induced… | National Institute on Aging | $9,337,034 |
About Hesperos, Inc.
Hesperos, Inc. is a leading company specializing in organ-on-a-chip technology, providing innovative solutions for drug testing and efficacy prediction to federal agencies. The company leverages its patented multi-organ functional systems to develop advanced in vitro models for preclinical research, particularly in the areas of rare diseases, neurodegenerative disorders, and toxicology. Hesperos, Inc. has been registered to receive federal awards since October 2014 and has secured both contract and grant awards from various agencies within the Department of Health and Human Services, primarily the National Institutes of Health (NIH).
Through federal contracts, Hesperos, Inc. has provided scientific testing services and technical expertise to support research programs at NIH. Notable projects include a $32,235 purchase order from the NIH Office of Logistics and Acquisition Operations for unspecified goods or services, likely related to their organ-on-a-chip technology. The company also received a $142,843 contract from the National Center for Advancing Translational Sciences (NCATS) for target validation and therapeutic evaluation of drug compounds in NGLY1 deficient cell-based models, including motoneurons and neuromuscular junction models. Additionally, Hesperos was awarded $159,282 by NCATS to gather data and screen drug compounds to ameliorate NGLY1 dysfunction. These contracts demonstrate Hesperos' capability to provide specialized in vitro testing services for rare disease research and drug development.
Hesperos, Inc. has secured significant federal grant funding to advance its organ-on-a-chip technology and develop novel preclinical screening platforms. A notable award is a $1,000,000 cooperative agreement from NCATS to develop and validate a high-throughput human Neuromuscular Junction platform for evaluating botulinum toxin potency, aiming to replace animal testing methods. The National Institute on Aging awarded Hesperos a $4,837,042 project grant to create an innovative human cell-based model for assessing anticholinergic drug properties and their association with dementia and Alzheimer's disease risk. This project integrates neuronal, blood-brain barrier, and liver modules to evaluate drug combinations and metabolic interactions. Additionally, Hesperos received a project grant from the National Institute of Environmental Health Sciences for biodistribution and pharmacokinetic modeling of rat versus human systems, further expanding their capabilities in comparative toxicology and drug metabolism research.
Quick answers
What is Hesperos, Inc.'s UEI?
Hesperos, Inc.'s Unique Entity ID (UEI) in SAM.gov is R1LSLA5YJMJ9.
What is Hesperos, Inc.'s CAGE code?
Hesperos, Inc.'s CAGE code is 79R15.
What is Hesperos, Inc.'s primary NAICS code?
Hesperos, Inc.'s primary NAICS code is 541714 (Research and Development in Biotechnology (except Nanobiotechnology)).
Where is Hesperos, Inc. located?
Hesperos, Inc.'s physical address in SAM.gov is 12501 Research Pkwy #100, Orlando, FL 32826, USA.
Is Hesperos, Inc. registered in SAM.gov?
Yes. Hesperos, Inc.'s SAM.gov registration is active through December 4, 2026.
What is Hesperos, Inc.'s most recent federal award?
Hesperos, Inc.'s most recent federal grant award is Expanded implementation of a human-based malaria-on-a-chip phenotypic disease model for the evaluation of therapeutic… (R44AI197758), from National Institute of Allergy and Infectious Diseases, on September 1, 2026.
On GovTribe
See Hesperos, Inc.'s full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors